TLR9-targeted STAT3 silencing abrogates immunosuppressive activity of myeloid-derived suppressor cells from prostate cancer patients

Clinical Cancer Research

Volumn 21, Issue 16, 2015, Pages 3771-3782

  Hossain, Dewan M S ^a   Pal, Sumanta K ^a   Moreira, Dayson ^a   Duttagupta, Priyanka ^a   Zhang, Qifang ^a   Won, Haejung ^a   Jones, Jeremy ^a   D'Apuzzo, Massimo ^a   Forman, Stephen ^a   Kortylewski, Marcin ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CPG OLIGODEOXYNUCLEOTIDE; DOCETAXEL; GAMMA INTERFERON; GRANZYME B; SMALL INTERFERING RNA; STAT3 PROTEIN; TOLL LIKE RECEPTOR 9; STAT3 PROTEIN, HUMAN; TLR9 PROTEIN, HUMAN;

ADVANCED CANCER; ARTICLE; ASSAY; BLOOD SAMPLING; BONE MARROW CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CD8+ T LYMPHOCYTE; CELL HETEROGENEITY; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE PROLIFERATION; METASTASIS; MULTIPLE CYCLE TREATMENT; MYELOID DERIVED SUPPRESSOR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; SUPPRESSOR CELL; TUMOR ESCAPE; BIOSYNTHESIS; BLOOD; CELL LINEAGE; CELL PROLIFERATION; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TUMOR EMBOLISM;

CD8-POSITIVE T-LYMPHOCYTES; CELL LINEAGE; CELL PROLIFERATION; GENE SILENCING; HUMANS; IMMUNOSUPPRESSION; LYMPHOCYTE ACTIVATION; MALE; MYELOID CELLS; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TOLL-LIKE RECEPTOR 9; TUMOR ESCAPE;

EID: 84942897448     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3145     Document Type: Article

References (50)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
3. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363:411-22.
4. Whiteside TL. Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression. Expert Opin Biol Ther 2010;10:1019-35.
5. May KF Jr, Gulley JL, Drake CG, Dranoff G, Kantoff PW. Prostate cancer immunotherapy. Clin Cancer Res 2011;17:5233-8.
6. Sottnik JL, Zhang J, Macoska JA, Keller ET. The PCa tumor microenvironment. Cancer Microenviron 2011;3:283-97.
7. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
8. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012;12:253-68.
9. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatictumorburden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009;58:49-59.
10. Greten TF, Manns MP, Korangy F. Myeloid derived suppressor cells in human diseases. Int Immunopharmacol 2011;11:802-7.
11. Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nat Immunol 2013;14:211-20.
12. Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al. Immunosuppressive CD14+HLA-DRlow/-monocytes in prostate cancer. Prostate 2009;70:443-55.
13. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H, et al. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 2008;14:8270-8.
14. Rodriguez PC, Ernstoff MS, Hernandez C, Atkins M, Zabaleta J, Sierra R, et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res 2009;69:1553-60.
15. Ko JS, Zea AH, Rini BI, Ireland JL, Elson P, Cohen P, etal. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res 2009;15:2148-57.
16. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, et al. Circulating and tumor-infiltrating myeloid cell subsets in patients with bladder cancer. Int J Cancer 2012;130:1109-19.
17. Highfill SL, Cui Y, Giles AJ, Smith JP, Zhang H, Morse E, et al. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci Transl Med 2014;6:237ra67.
18. Pal SK, Sakib Hossain DM, Zhang Q, Frankel PH, Jones JO, Carmichael C, etal. Pazopanib as third-line therapy for metastatic renal cell carcinoma: clinical efficacy and temporal analysis of cytokine profile. J Urol 2014;14:4591-1.
19. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74.
20. Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007;7:41-51.
21. Vasquez-Dunddel D, Pan F, Zeng Q, Gorbounov M, Albesiano E, Fu J, et al. STAT3 regulates arginase-I in myeloid-derived suppressor cells from cancer patients. J Clin Invest 2013;123:1580-9.
22. Wesolowski R, Markowitz J, Carson WE III. Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer 2013;1:10.
23. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009;27:925-32.
24. Zhang Q, Hossain DM, Nechaev S, Kozlowska A, Zhang W, Liu Y, et al. TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. Blood 2013;121:1304-15.
25. Gao C, Kozlowska A, Nechaev S, Li H, Zhang Q, Hossain DM, et al. TLR9 signaling in the tumor micro environment initiates cancer recurrence after radiotherapy. Cancer Res 2013;73:7211-21.
26. Waight JD, Hu Q, Miller A, Liu S, Abrams SI. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS One 2011;6:e27690.
27. Poschke I, Mougiakakos D, Hansson J, Masucci GV, Kiessling R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res 2010;70:4335-45.
28. Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010;16:4583-94.
29. Brandau S, Moses K, Lang S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: cousins, siblings or twins? Semin Cancer Biol 2013;23:171-82.
30. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J Clin Invest 2012;122:327-36.
31. Mace TA, Ameen Z, Collins A, Wojcik S, Mair M, Young GS, et al. Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner. Cancer Res 2013;73:3007-18.
32. Yu J, Wang Y, Yan F, Zhang P, Li H, Zhao H, et al. Noncanonical NF-kappaB activation mediates STAT3-stimulated IDO upregulation in myeloidderived suppressor cells in breast cancer. J Immunol 2014;193:2574-86.
33. Waight JD, Netherby C, Hensen ML, Miller A, Hu Q, Liu S, et al. Myeloidderived suppressor cell development is regulated by a STAT/IRF-8 axis. J Clin Invest 2013;123:4464-78.
34. Zoglmeier C, Bauer H, Norenberg D, Wedekind G, Bittner P, Sandholzer N, et al. CpG blocks immunosuppressionbymyeloid-derived suppressor cells in tumor-bearing mice. Clin Cancer Res 2011;17:1765-75.
35. Shirota Y, Shirota H, Klinman DM. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol 2012;188:1592-9.
36. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. AToll-like receptor recognizes bacterial DNA. Nature 2000;408:740-5.
37. Hayashi F, Means TK, Luster AD. Toll-like receptors stimulate human neutrophil function. Blood 2003;102:2660-9.
38. Hoene V, Peiser M, Wanner R. Human monocyte-derived dendritic cells expressTLR9 and react directlytothe CpG-A oligonucleotide D19. J Leukoc Biol 2006;80:1328-36.
39. Trinchieri G, Sher A. Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007;7:179-90.
40. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010;11:373-84.
41. Murray PJ, Smale ST. Restraint of inflammatory signaling by interdependent strata of negative regulatory pathways. Nat Immunol 2012;13:916-24.
42. Krieg AM. CpG still rocks! Updateonanaccidental drug. Nucleic Acid Ther 2012;22:77-89.
43. El Kasmi KC, Qualls JE, Pesce JT, Smith AM, Thompson RW, Henao-Tamayo M, et al. Toll-like receptor-induced arginase 1 in macrophages thwarts effective immunity against intracellular pathogens. Nat Immunol 2008;9:1399-406.
44. Parker KH, Sinha P, Horn LA, Clements VK, Yang H, Li J, et al. HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells. Cancer Res 2014;74:5723-33.
45. Hsu K, Chung YM, Endoh Y, Geczy CL. TLR9 ligands induce S100A8 in macrophages via a STAT3-dependent pathway which requires IL-10 and PGE2. PLoS ONE 2014;9:e103629.
46. Kortylewski M, Kujawski M, Herrmann A, Yang C, Wang L, Liu Y, etal. Toll-like receptor 9 activation of signal transducer and activator of transcription 3 constrainsitsagonist-based immunotherapy. Cancer Res 2009;69:2497-505.
47. Kujawski M, Zhang C, Herrmann A, Reckamp K, Scuto A, Jensen M, et al. Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effects. Cancer Res 2010;70:9599-610.
48. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009;206:1457-64.
49. Kaech SM, Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat Rev Immunol 2012;12:749-61.
50. Maenhout SK, Du Four S, Corthals J, Neyns B, Thielemans K, Aerts JL. AZD1480 delays tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-derived suppressor cells. Oncotarget 2014;5:6801-15.